AU2004207576B8 - Antisense oligonucleotides that inhibit expression of HIF-1 - Google Patents

Antisense oligonucleotides that inhibit expression of HIF-1 Download PDF

Info

Publication number
AU2004207576B8
AU2004207576B8 AU2004207576A AU2004207576A AU2004207576B8 AU 2004207576 B8 AU2004207576 B8 AU 2004207576B8 AU 2004207576 A AU2004207576 A AU 2004207576A AU 2004207576 A AU2004207576 A AU 2004207576A AU 2004207576 B8 AU2004207576 B8 AU 2004207576B8
Authority
AU
Australia
Prior art keywords
hif
compound
oligonucleotide
cells
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004207576A
Other languages
English (en)
Other versions
AU2004207576A1 (en
AU2004207576B2 (en
Inventor
Chang-Ho Ahn
Xiaoming Jiang
Young Bok Lee
Lingjun Mao
Heejeong Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of AU2004207576A1 publication Critical patent/AU2004207576A1/en
Assigned to REXAHN PHARMACEUTICALS, INC. reassignment REXAHN PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: REXAHN CORPORATION
Application granted granted Critical
Publication of AU2004207576B2 publication Critical patent/AU2004207576B2/en
Publication of AU2004207576B8 publication Critical patent/AU2004207576B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004207576A 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of HIF-1 Ceased AU2004207576B8 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76618503A 2003-01-28 2003-01-28
US44436703P 2003-01-31 2003-01-31
US60/444,367 2003-01-31
PCT/US2004/002344 WO2004066949A2 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of hif-1

Publications (3)

Publication Number Publication Date
AU2004207576A1 AU2004207576A1 (en) 2004-08-12
AU2004207576B2 AU2004207576B2 (en) 2008-10-23
AU2004207576B8 true AU2004207576B8 (en) 2008-11-20

Family

ID=32829853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004207576A Ceased AU2004207576B8 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of HIF-1

Country Status (3)

Country Link
JP (1) JP4546454B2 (enExample)
AU (1) AU2004207576B8 (enExample)
WO (1) WO2004066949A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011353283A1 (en) 2010-12-30 2013-07-18 Samyang Biopharmaceuticals Corporation siRNA for inhibition of Hif1alpha expression and anticancer composition containing the same
US10307490B2 (en) * 2012-05-23 2019-06-04 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076497A1 (en) * 1999-06-14 2000-12-21 Cancer Research Ventures Limited Cancer therapy
WO2002034291A2 (en) * 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
HUE037352T2 (hu) * 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As A HIF-1alfa expresszálódását módosító oligomer vegyületek
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076497A1 (en) * 1999-06-14 2000-12-21 Cancer Research Ventures Limited Cancer therapy
WO2002034291A2 (en) * 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance

Also Published As

Publication number Publication date
WO2004066949A3 (en) 2005-12-01
AU2004207576A1 (en) 2004-08-12
JP4546454B2 (ja) 2010-09-15
JP2006520195A (ja) 2006-09-07
AU2004207576B2 (en) 2008-10-23
WO2004066949A8 (en) 2004-11-11
WO2004066949A2 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
JP2013165733A (ja) Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
KR20110017005A (ko) Ｔｇｆ-베타 수용체 유전자 발현 억제용 조성물 및 방법
US7122527B2 (en) Use of antisense oligonucleotides to inhibit the expression of human Akt-1
CA2513398C (en) Antisense oligonucleotides that inhibit expression of hif-1
EP2481801A1 (en) Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
US20050153918A1 (en) Methods and compositions relating to hnRNP A1, A1B, A2, and B1 nucleic acid molecules
AU2004207576B2 (en) Antisense oligonucleotides that inhibit expression of HIF-1
US20020068711A1 (en) Arrest of proliferation of highly glycolytic tumors
Zvereva et al. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics
US20060089322A1 (en) Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
US20050191672A1 (en) Antisense oligonucleotides and RNA-interfering molecules targeting PAK4
WO2024254092A2 (en) Methods and compositions for treating neurological diseases and disorders and cancers
US10443057B2 (en) Multi-targets interfering RNA molecules and their applications
CA2534996A1 (en) The use of sirna silencing in the prevention of metastasis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: REXAHN PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): REXAHN CORPORATION

TH Corrigenda

Free format text: IN VOL 22, NO 13, PAGE(S) 1428 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 -2004 DELETEALL REFERENCE TO APPLICATION NO. 2004207576

TH Corrigenda

Free format text: IN VOL 22, NO 42, PAGE(S) 5002 UNDER THE HEADING APPLICATIONS ACCEPTED -NAME INDEX UNDER THE NAME REXAHN PHARMACEUTICALS, INC., APPLICATION NO. 2004207576, UNDER INID(31) CORRECT THE PRIOPITY DETAILS TO 60/444,367 US 31 JANUARY 2003

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired